chartexchange

SVRA
Savara Inc.
stockNASDAQ

Market OpenNov 19, 2026 3:00:20 PM EST
5.22USD+10.593%(+0.50)10,035,243
Pre-marketNov 19, 2026 9:29:30 AM EST
4.82USD+2.119%(+0.10)
5.2200Bid5.2300Ask0.0100Spread
Loading…
Loading…
Healthcare
Biotechnology
CEO
Robert Neville
HQ
Austin, TX, USA
Previous Close
$4.72
Beta
1.39
52-Week High
$7.01 2025-12-12
52-Week Low
$4.13 2026-10-23
SMA 50
$4.88
SMA 200
$5.32
Avg. Vol 10D
3.82M
Avg. Vol 30D
2.90M
Avg. Vol 90D
2.18M
Relative Vol
3.42
220.62M
110.58M
32,273,605
0.4100%
204
Apr 26, 2010 · 1-for-25 (reverse)
SVRA Profile

savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company's lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara's website at www.savarapharma.com or www.aerovanc.com

SVRA Performance
PeriodPriceDateChangeBeta
1W4.722026-11-12+10.70%3.606
1M4.632026-10-19+12.85%1.791
3M5.582026-08-19-6.36%1.543
6M4.722026-05-19+10.70%1.204
1Y4.602025-11-19+13.59%1.388
2Y2.942024-11-19+77.72%—
5Y1.082021-11-19+383.80%0.912
SVRA Stock Summary

Savara Inc. (NASDAQ:SVRA) stock price today is $5.23, and today's volume is 9,895,528. SVRA is up 10.699% today. The 30 day average volume is 2.90M. SVRA market cap is $1.15B with 220.62M shares outstanding.